BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the 10 most shorted biotech stocks to buy according to hedge funds.

On March 2, Wedbush analyst Laura Chico increased the firm’s price target on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to $22 from $21. The analyst maintained her Outperform rating on the stock. Although the company had previously preannounced its fourth quarter results and FY26 guidance, additional details were provided following the completion of the Astria Therapeutics acquisition. Management maintained its forward guidance for FY26, along with the peak revenue targets.

Chico views the company’s commercial business as operating smoothly, with additional data from BCX17725 expected by the end of 2026. She continues to view the current setup for BioCryst shares favorably based on the company’s ongoing commercial performance.

On February 26, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) reported its fourth quarter EPS of $1.12 compared to a loss of 13c in 2024. The company posted quarter revenues of $406.5 million, up from $131.5 million during the same period last year. Charlie Gayer, President and Chief Executive Officer of BioCryst, stated:

2025 was fundamentally transformative for BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX). We achieved full-year profitability for the first time in the company’s history, driven by strong commercial execution that delivered the highest level of new patient prescriptions in the U.S. since the initial launch of ORLADEYO, even as the treatment landscape continued to evolve. We also advanced key business development initiatives that streamlined our operations and further strengthened our leadership position in hereditary angioedema. We entered 2026 with strong momentum, completing the acquisition of Astria Therapeutics to grow our HAE portfolio to meet the needs of more patients, while adding to our long-term growth trajectory well into the next decade.

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is a biotech company that creates treatments for rare and hard-to-treat diseases. Their biggest products help people manage influenza and hereditary angioedema. They also have several promising new medicines in clinical trials, working alongside major pharmaceutical partners to bring more breakthrough treatments to patients.

While we acknowledge the potential of BCRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.